Royal Philips (NYSE:PHG) announced today that one-year results of its Define PCI study that reported improved outcomes and less recurrent angina.
The Define PCI study assessed the level of residual ischemia found in patients following a percutaneous coronary intervention (PCI) using a blinded instant wave-free ratio (iFR) pullback measurement, which is a guidance technology unique to Philips, according to a news release.
“In Define PCI we noted that if all lesions causing focal ischemia had been treated up-front, the rate of significant ischemia could theoretically be reduced from 24% to 5%,” principal investigator Dr. Allen Jeremias said in the release. “Now with the one-year data, we find that patients with more complete resolution of ischemia do better clinically.”
Amsterdam-based Philips said the one-year data release shows patients whose baseline ischemia was more effectively treated by the company showed improved outcomes and less recurrent angina with an optimal post-PCI iFR associated with improved event-free survival.
The data follows 500 patients over the course of the one year, with initial results showing that one in four patients treated with standard of care PCI left the lab with residual ischemia.
“The one-year data from DEFINE PCI are the latest evidence that iFR contributes to reduced costs, enhanced patient experience and improved outcomes for PCI procedures [2, 3, 4],” Philips senior VP & GM of image-guided therapy devices Chris Landon said. “With the recent introduction of OmniWire, the world’s first solid core pressure guidewire for coronary artery interventional procedures, as well as the next generation of our Azurion platform, we are advancing image-guided therapy with innovative, procedure-focused solutions.”
